Product Information
AFIRMELLE-28 TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1584 per EA under NDC 65862084988. Its NADAC has been published 314 times since Aug 21, 2019.
FDA first approved this application on Nov 14, 2016. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Aurobindo Pharma LimitedNDC
65862084988
Classification
Generic
Dosage Form
KIT
Effective Date
8/20/2025
Approval Type
Generic (ANDA)
FDA Application
ANDA206886FDA Approved
11/14/2016
TE Code
AB1
On Market Since
11/14/2016
Price Statistics
The NADAC for AFIRMELLE-28 TABLET has been published 314 times since Aug 21, 2019, and over the history we have for it it has declined 58.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1584 per EA |
|---|---|
| All-time high | $0.3780 (Sep 11, 2019) |
| All-time low | $0.1212 (Jul 17, 2024) |
| Median price | $0.2057 |
| Average price | $0.2138 |
| Largest weekly change | +35.3% (Jun 19, 2024) |
| Weeks tracked | 314 |
| Tracking since | Aug 21, 2019 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-11.7%
5Y
-30.5%
All
-58.1%
Last surveyed Aug 20, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 28% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levonorgestrel and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AFIRMELLE-28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AFIRMELLE-28 TABLET, manufactured by Aurobindo Pharma Limited, is $0.1584 per EA (NDC 65862084988), effective Aug 20, 2025.
How has the price of AFIRMELLE-28 TABLET changed over time?
Over the history we have for it, the NADAC for AFIRMELLE-28 TABLET has declined 58.1%. It has been tracked across 314 weekly CMS publications since Aug 21, 2019.
What are the highest and lowest recorded NADAC prices for AFIRMELLE-28 TABLET?
Since Aug 21, 2019, the NADAC for AFIRMELLE-28 TABLET has ranged from a low of $0.1212 (Jul 17, 2024) to a high of $0.3780 (Sep 11, 2019), with a median of $0.2057 per EA.
Are there cheaper alternatives to AFIRMELLE-28 TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CHATEAL EQ-28 TABLET, is $0.1135 per EA — about 28% below AFIRMELLE-28 TABLET.
Who manufactures AFIRMELLE-28 TABLET?
AFIRMELLE-28 TABLET (NDC 65862084988) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.